MY195576A - Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof - Google Patents
Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use ThereofInfo
- Publication number
- MY195576A MY195576A MYPI2019003964A MYPI2019003964A MY195576A MY 195576 A MY195576 A MY 195576A MY PI2019003964 A MYPI2019003964 A MY PI2019003964A MY PI2019003964 A MYPI2019003964 A MY PI2019003964A MY 195576 A MY195576 A MY 195576A
- Authority
- MY
- Malaysia
- Prior art keywords
- kinase inhibitors
- pharmaceutical use
- janus kinase
- novel amino
- imidazopyridine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17151020 | 2017-01-11 | ||
| PCT/EP2018/050548 WO2018130563A1 (en) | 2017-01-11 | 2018-01-10 | Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY195576A true MY195576A (en) | 2023-02-02 |
Family
ID=57777557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019003964A MY195576A (en) | 2017-01-11 | 2018-01-10 | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10703751B2 (OSRAM) |
| EP (1) | EP3568396B1 (OSRAM) |
| JP (1) | JP7009504B2 (OSRAM) |
| KR (1) | KR102548543B1 (OSRAM) |
| CN (1) | CN110167938B (OSRAM) |
| AU (1) | AU2018208516B2 (OSRAM) |
| CA (1) | CA3045567A1 (OSRAM) |
| CY (1) | CY1123864T1 (OSRAM) |
| DK (1) | DK3568396T3 (OSRAM) |
| ES (1) | ES2846741T3 (OSRAM) |
| HR (1) | HRP20210095T1 (OSRAM) |
| HU (1) | HUE052720T2 (OSRAM) |
| IL (1) | IL267829B (OSRAM) |
| LT (1) | LT3568396T (OSRAM) |
| MX (1) | MX389378B (OSRAM) |
| MY (1) | MY195576A (OSRAM) |
| NZ (1) | NZ754922A (OSRAM) |
| PL (1) | PL3568396T3 (OSRAM) |
| PT (1) | PT3568396T (OSRAM) |
| RS (1) | RS61317B1 (OSRAM) |
| RU (1) | RU2019125177A (OSRAM) |
| SI (1) | SI3568396T1 (OSRAM) |
| TW (1) | TWI760419B (OSRAM) |
| UA (1) | UA123972C2 (OSRAM) |
| WO (1) | WO2018130563A1 (OSRAM) |
| ZA (1) | ZA201904190B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| PL3555097T3 (pl) | 2016-12-16 | 2022-10-17 | Janssen Pharmaceutica Nv | Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| WO2020007698A1 (en) * | 2018-07-06 | 2020-01-09 | Leo Pharma A/S | Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof |
| JP7345220B2 (ja) * | 2019-08-30 | 2023-09-15 | ティーエスディー ライフ サイエンス カンパニー リミテッド | イミダゾピリジン誘導体及びこれを有効成分として含有する薬学的組成物 |
| BR112023018286A2 (pt) | 2021-03-11 | 2023-10-31 | Janssen Pharmaceutica Nv | Lorpucitinib para uso no tratamento de distúrbios mediados por jak |
| CN119569971B (zh) * | 2025-02-07 | 2025-05-27 | 吉林大学 | 一种用于蛋白质磷酸化和棕榈酰化修饰同时筛选的Janus材料的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8389527B2 (en) * | 2008-02-06 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| EP2523957A1 (en) * | 2010-01-12 | 2012-11-21 | F. Hoffmann-La Roche AG | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| RU2013109143A (ru) * | 2010-08-05 | 2014-09-10 | Амджен Инк. | Бензимидазол- и азабензимидазолсодержащие соединения, которые ингибируют киназу анапластической лимфомы |
| EP2518071A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
| EP2527344A1 (en) * | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| WO2013007768A1 (en) * | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| UY34616A (es) * | 2012-02-10 | 2013-09-30 | Galapagos Nv | Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias. |
| BR112015009942A2 (pt) | 2012-11-01 | 2017-07-11 | Incyte Corp | derivados de tiofeno fundidos tricíclicos como inibidores de jak |
| WO2014081718A1 (en) * | 2012-11-20 | 2014-05-30 | Genentech, Inc. | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| CN104098563A (zh) * | 2013-04-02 | 2014-10-15 | 山东亨利医药科技有限责任公司 | Jnk抑制剂化合物 |
| SG11201609016VA (en) * | 2014-04-30 | 2016-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
| EA201990523A1 (ru) * | 2016-10-03 | 2019-10-31 | НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ | |
| JOP20190144A1 (ar) * | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
-
2018
- 2018-01-10 UA UAA201908568A patent/UA123972C2/uk unknown
- 2018-01-10 SI SI201830191T patent/SI3568396T1/sl unknown
- 2018-01-10 DK DK18702412.0T patent/DK3568396T3/da active
- 2018-01-10 EP EP18702412.0A patent/EP3568396B1/en active Active
- 2018-01-10 MX MX2019008331A patent/MX389378B/es unknown
- 2018-01-10 RS RS20210044A patent/RS61317B1/sr unknown
- 2018-01-10 RU RU2019125177A patent/RU2019125177A/ru unknown
- 2018-01-10 CA CA3045567A patent/CA3045567A1/en active Pending
- 2018-01-10 PL PL18702412T patent/PL3568396T3/pl unknown
- 2018-01-10 HU HUE18702412A patent/HUE052720T2/hu unknown
- 2018-01-10 US US16/477,249 patent/US10703751B2/en active Active
- 2018-01-10 PT PT187024120T patent/PT3568396T/pt unknown
- 2018-01-10 NZ NZ754922A patent/NZ754922A/en unknown
- 2018-01-10 CN CN201880006261.0A patent/CN110167938B/zh active Active
- 2018-01-10 AU AU2018208516A patent/AU2018208516B2/en active Active
- 2018-01-10 MY MYPI2019003964A patent/MY195576A/en unknown
- 2018-01-10 JP JP2019557681A patent/JP7009504B2/ja active Active
- 2018-01-10 KR KR1020197021697A patent/KR102548543B1/ko active Active
- 2018-01-10 ES ES18702412T patent/ES2846741T3/es active Active
- 2018-01-10 WO PCT/EP2018/050548 patent/WO2018130563A1/en not_active Ceased
- 2018-01-10 HR HRP20210095TT patent/HRP20210095T1/hr unknown
- 2018-01-10 LT LTEP18702412.0T patent/LT3568396T/lt unknown
- 2018-01-11 TW TW107101035A patent/TWI760419B/zh active
-
2019
- 2019-06-26 ZA ZA2019/04190A patent/ZA201904190B/en unknown
- 2019-07-03 IL IL267829A patent/IL267829B/en unknown
-
2021
- 2021-02-01 CY CY20211100085T patent/CY1123864T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| PH12022551014A1 (en) | Substituted tricyclic compounds | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| NZ777871A (en) | Small molecule modulators of il-17 | |
| MX2020001776A (es) | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. | |
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| TW200833675A (en) | Nicotinamide derivatives | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| PH12021551873A1 (en) | Hydroxypyridoxazepines as nrf2 activators | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| MX2023003576A (es) | Compuesto como inhibidor de la akt cinasa. | |
| PH12022552727A1 (en) | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE | |
| SA521431279B1 (ar) | D1 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي | |
| PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| MX379704B (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida | |
| PH12022550860A1 (en) | 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists | |
| PH12022550859A1 (en) | 2-azaspiro[3.4]octane derivatives as m4 agonists |